Atlas Venture Fund XI, L.P. bought $1.1M of Sionna Therapeutics (SION)
Executed Feb 10 2025, disclosed Feb 10 2025, the same day.
Over the 21 trading sessions from the disclosed entry session (Feb 10 2025), the stock returned -31.5% (delay-adjusted); from the execution session (Feb 10 2025), -31.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
Atlas Venture Fund XI, L.P. (10% owner) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in Sionna Therapeutics, Inc. (SION). Across 1 priced purchase filing, the average 21-session return was -31.5% from execution and -31.5% from disclosure (delay-adjusted; derived). The largest single filing was $1.1M of SION (60,000 sh × $18.00, as filed), executed Feb 10 2025.
Healthcare · Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibros…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→